Esketamine Maintenance Dosing for Sustained Depression Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an effective, long-term, and safe treatment for depression, particularly in patients diagnosed as having treatment-refractory or treatment-resistant depression, as existing treatments like esketamine show limited sustained antidepressant effects and potential neurotoxicity concerns.
Innovation Solution
Administer esketamine in combination with at least one antidepressant, initially twice weekly during an induction phase, followed by reinitiating the highest tolerable dose with a second antidepressant in a second induction phase, and continuing esketamine treatment for at least six months to achieve long-term treatment of treatment-resistant depression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If esketamine is administered at low, subanesthetic doses, then antidepressant effect is achieved, but the duration of action is limited and sustained effect cannot be maintained
Solution Approach 1:
The patent implements an induction phase with frequent dosing (twice weekly) before transitioning to maintenance dosing. This preliminary intensive treatment phase prepares the system by establishing initial therapeutic effect and neuroplastic changes, which then enables sustained response at lower maintenance doses, resolving the contradiction between achieving reliable antidepressant effect and maintaining duration of action
Solution Approach 2:
The patent employs periodic dosing schedules with an induction phase (twice weekly for 4 weeks) followed by maintenance phases with varying frequencies (once weekly, once every two weeks, or once monthly). This periodic action pattern allows the antidepressant effect to be reliably initiated and then sustained over extended periods through strategically timed dosing intervals
2Duration of action of stationary object
If esketamine is administered repeatedly over long term, then sustained antidepressant effect may be achieved, but neurotoxicity risk increases
Solution Approach 1:
The patent implements dynamic dosing adjustment where the frequency and amount of esketamine administration are adapted based on individual patient response and tolerability. The induction phase uses higher frequency (twice weekly) followed by progressively spaced maintenance dosing (weekly, biweekly, or monthly), allowing long-term treatment while minimizing neurotoxicity risk through personalized dynamic adjustment rather than fixed dosing
Solution Approach 2:
The patent changes dosing parameters (frequency and amount) based on patient response during induction and maintenance phases. By adjusting these parameters individually for each patient, the treatment can be continued long-term to achieve sustained antidepressant effect while keeping the actual dose and frequency at tolerable levels to reduce neurotoxicity risk
3Reliability
If esketamine is administered alone, then treatment simplicity is maintained, but treatment efficacy for treatment-resistant depression is insufficient
Solution Approach 1:
The patent combines esketamine administration with continuation of oral antidepressant therapy that the patient is already receiving. This merging of treatments allows esketamine to provide the breakthrough efficacy needed for treatment-resistant depression while the oral antidepressant maintains baseline treatment, achieving enhanced reliability without requiring complete discontinuation of existing therapy
Solution Approach 2:
The oral antidepressant serves as an intermediary that bridges the gap between standard treatment and esketamine therapy. It maintains continuous baseline treatment while esketamine provides the additional therapeutic push needed for treatment-resistant cases, allowing combination therapy to be more tolerable and manageable than complete treatment overhaul
4Reliability
If induction phase with frequent dosing is implemented, then initial antidepressant response is achieved, but treatment time and resource consumption increase
Solution Approach 1:
The induction phase uses accelerated frequent dosing (twice weekly) for a limited period (4 weeks) to rapidly achieve therapeutic effect and cross the threshold into sustained response. This rushing through the critical initial phase establishes treatment efficacy quickly, after which maintenance dosing can proceed at lower frequency, minimizing the time loss associated with intensive induction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy with esketamine and antidepressants provides sustained antidepressant effects, maintaining stable remission or response for extended periods, reducing the risk of neurotoxicity and improving patient outcomes.
Implementation Method 1
Ketamine (a racemic mixture of the corresponding S- and R-enantiomers) is a nonselective antagonist at the phencyclidine binding site of the glutamate N-methyl-D-aspartate (NMDA) receptor
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.